Ebola virus (EBOV) causes hemorrhagic fever, resulting in mortality rates as high as 90% among infected humans and non-human primates (NHPs). The 2014 Ebola epidemic in West Africa is the severest in history, leading to WHO taking all control measures to stop any possibility of cross-border outbreaks. Because no licensed vaccines or effective therapeutics against EBOV are available, the current outbreak management has been limited to palliative care and barrier methods to prevent transmission. Several promising experimental EBOV vaccines have demonstrated protection in NHPs against lethal EBOV challenge, and some progresses have been made through clinical trials of EBOV vaccine candidates. It is believed there will be some licensed vaccine available in the near future to control EBOV outbreaks. In this review we provide some insights for further development of EBOV vaccines.
Animals ; Ebola Vaccines ; Ebolavirus ; Hemorrhagic Fever, Ebola ; prevention & control ; Humans

Hemorrhagic Fever, Ebola ; diagnosis ; drug therapy ; epidemiology ; prevention & control ; Humans

China ; Hemorrhagic Fever, Ebola ; prevention & control ; Humans ; Influenza, Human ; epidemiology ; prevention & control ; Research

Starting from February 2014, the Ebola virus outbreak had spread across West African countries within a few months and caused great concerns of the World Health Organization. Currently no effective vaccines or drugs have been available for prevention and treatment of Ebola virus infection. This paper gives a brief review of the epidemics and pandemics, the biological characteristics of Ebola virus, the potential antiviral drug targets, and research progress of vaccine and drug development against the virus.
Antiviral Agents ; therapeutic use ; Ebolavirus ; Hemorrhagic Fever, Ebola ; prevention & control ; therapy ; Humans

Disease Outbreaks ; Hemorrhagic Fever, Ebola ; epidemiology ; history ; prevention & control ; History, 21st Century ; Humans ; Sierra Leone ; epidemiology

OBJECTIVE: To analyze the global epidemic status of the Ebola virus disease (EVD) and assess the importation risk into China. METHODS: Data from World Health Organization reports were used. We described the global epidemic status of EVD from 1976-2021, and assessed and ranked the importation risk of EVD from the disease-outbreaking countries into China using the risk matrix and Borda count methods, respectively. RESULTS: From 1976-2021, EVD mainly occurred in western and central Africa, with the highest cumulative number of cases (14,124 cases) in Sierra Leone, and the highest cumulative fatality rate (85%) in the Congo. Outbreaks of EVD have occurred in the Democratic Republic of the Congo and Guinea since 2018. The importation risk into China varies across countries with outbreaks of disease. The Democratic Republic of the Congo had an extremely high risk (23 Borda points), followed by Guinea and Liberia. Countries with a moderate importation risk were Nigeria, Uganda, Congo, Sierra Leone, Mali, and Gabon, while countries with a low importation risk included Sudan, Senegal, and Co^te d'Ivoire. CONCLUSION China is under the risk of EVD importation with the globalization and severe epidemic status of EVD. Key attention need to be paid to the Democratic Republic of the Congo, Guinea, and Liberia. Therefore, it is necessary to prevent and prepare in advance for importation risk in China.
Humans ; Hemorrhagic Fever, Ebola/prevention & control* ; Epidemics ; Disease Outbreaks/prevention & control* ; Guinea/epidemiology* ; Sierra Leone/epidemiology* ; China/epidemiology*

The Ebola virus belongs to the Filovirus family, which causes Ebola hemorrhagic fever (mortality, 25%-90%). An outbreak of infection by the Ebola virus is sweeping across West Africa, leading to high mortality and worldwide panic. The Ebola virus has caused a serious threat to public health, so intensive scientific studies have been carried out. Several vaccines (e.g., rVSV-ZEBOV, ChAd3-ZEBOV) have been put into clinical trials and antiviral drugs (e.g., TKM-Ebola, ZMAPP) have been administered in the emergency setting to patients infected by the Ebola virus. Here, recent advances in vaccines and drugs against the Ebola virus are reviewed.
Animals ; Antiviral Agents ; administration & dosage ; Ebola Vaccines ; administration & dosage ; genetics ; immunology ; Ebolavirus ; drug effects ; genetics ; immunology ; physiology ; Hemorrhagic Fever, Ebola ; drug therapy ; prevention & control ; virology ; Humans

No abstract available.
Antiviral Agents/therapeutic use ; Hemorrhagic Fever, Ebola/drug therapy/*prevention & control/virology ; Humans ; Protective Devices ; Vaccines/immunology

No abstract available.
Antiviral Agents/therapeutic use ; Hemorrhagic Fever, Ebola/drug therapy/*prevention & control/virology ; Humans ; Protective Devices ; Vaccines/immunology